Global pharmaceutical companies are increasingly partnering with Chinese biotech firms to access innovative drug candidates and strengthen their research pipelines. Explore major licensing deals, oncology breakthroughs, AI-driven drug discovery, strategic partnerships, and the challenges shaping global pharmaceutical innovation
The global pharmaceutical industry is entering a new phase in which innovation is no longer concentrated in traditional research hubs across the United States and Europe. China is emerging as an important source of drug discovery, clinical development, and biotechnology innovation, attracting increasing interest from multinational pharmaceutical companies. From cancer treatment and autoimmune therapies to obesity medicines, Chinese biotechnology companies are developing drug candidates that global pharmaceutical companies want to commercialize in international markets.
This shift reflects changing priorities across the pharmaceutical industry. Large drug makers face pressure to replenish their research pipelines, develop differentiated treatments, manage research and development expenditure, and respond to growing competition. Instead of developing every medicine internally, companies are increasingly acquiring or licensing promising drug candidates from external innovators, including Chinese biotechnology firms.
According to a Reuters Breakingviews report published on October 16, 2026, Chinese drugmakers had signed overseas licensing agreements worth approximately US$139.4 billion by October 8, 2026, according to PharmCubs. This figure exceeded the US$128.8 billion recorded for the whole of 2025. The agreements cover drug innovations across areas such as cancer and obesity, highlighting China’s growing importance in international pharmaceutical dealmaking.
The trend also signals a change in the relationship between Chinese biotech companies and global pharmaceutical leaders. Chinese firms are increasingly negotiating larger upfront payments, milestone-based compensation, and equity participation instead of simply transferring their discoveries for limited returns.
Understanding China’s Growing Role in Pharmaceutical Innovation
China’s pharmaceutical innovation ecosystem includes biotechnology startups, established drugmakers, contract research organizations, academic research institutions, and specialized manufacturing companies. These organizations contribute to drug discovery, preclinical research, clinical trials, biological developments, and the advancement of targeted therapies.
Historically, many multinational pharmaceutical companies viewed China primarily as a manufacturing destination and a large medicines market. Its role is increasingly extending into early-stage research and the development of innovative drug candidates.
Chinese companies are advancing molecules and biological therapies designed to address unmet medical needs. These include oncology drugs, immune-modulating treatments, metabolic disease therapies, and other targeted medicines. Some candidates are developed for domestic patients before being licensed to international partners, while others are designed with global commercialization opportunities in mind.
The licensing model allows a Chinese biotechnology company to retain ownership of its innovation while granting a pharmaceutical partners rights to develop and commercialize the medicine in specific territories. The partner typically contributes developed expertise, regulatory capabilities, manufacturing resources, and access to established commercial networks.
These arrangements can benefit both parties. Chinese innovators gain funding and access to international markets, while multinational companies gain opportunities to strengthen their pipelines without having to discover every drug candidate themselves.
Why Global Pharmaceutical Companies Are Buying Innovation From China
Stronger Drug Development Pipelines
One of the biggest reasons global Pharmaceutical companies are turning to China is the need to replenish their drug development pipelines. Pharmaceutical companies must continually introduce new medicines to offset competition from generic drugs, patent expiration, and changing treatment standards.
Developing new medicines internally can require years of research, substantial investments, and multiple stages of clinical evaluation. Licensing a promising drug candidate from an external biotechnology company provides another route to access potential treatments and diversify research portfolios.
Chinese biotechnology companies are increasingly offering candidates across therapeutic areas, allowing multinational companies to evaluate opportunities that complement their existing research programs. However, licensing does not eliminate the need for clinical trials, regulatory review, or investment in commercialization.
Growing Innovation in Oncology and Targeted Therapies
Cancer treatment is an important area of opportunity for Chinese biotechnology companies. Researchers are developing targeted therapies, antibody-based medicines, immune-based treatments, and other approaches designed to address specific biological mechanisms involved in cancer.
These innovations are attractive to multinational pharmaceutical companies for patients with limited options. Drug candidates with differentiated mechanisms of action can also help companies expand their oncology portfolios and explore new treatment combinations.
Beyond cancer, Chinese developers are investigating therapies for autoimmune diseases, metabolic disorders, and obesity. The braoder range of research gives international pharmaceutical companies opportunities to diversify their pipelines rather than relying on a narrow group of therapeutic categories.
Nevertheless, the commercial value of any candidate depends on its clinical performance, safety profile, competitive position, and ability to demonstrate meaningful benefits for patients.
Faster Research and Development Opportunities
The pharmaceutical industry is under pressure to improve research productivity while managing development costs. China has developed an extensive ecosystem of biotechnology companies, clinical research organizations, scientific talent, and specialized service providers.
This ecosystem can support different stages of drug development, from laboratory research to clinical testing. Access to experienced researchers and established development infrastructure may help companies advance selected candidates efficiently.
For multinational drugmakers, licensing a candidate that has already generated promising early-stage data can provide a strategic starting point. The acquiring company can then assess whether additional clinical development is justified and determine the evidence needed for regulatory submission in its target markets.
However, faster development should not be confused with guaranteed approval. Drug candidates can fail during clinical trials, and evidence generated in one country may require additional evaluation before regulators in another jurisdiction accept it.
More Strategic Licensing and Commercial Partnerships
Licensing arrangements have become more sophisticated as Chinese biotechnology companies seek a greater share of the value created by their discoveries.
According to the Reuters Breakingviews report published on October 16, 2026, the average licensing agreement involving Chinese drugmakers was worth nearly US$700 million in 2026, including potential milestone payments. The report noted that this was more than ten times the average agreement value in 2018.
These headline figures require careful interpretation because milestone payments are generally conditional on development, regulatory, or commercial achievements. They do not represent cash received immediately by the companies signing the agreements.
Even so, rising upfront payments and more complex deal structures indicate that Chinese innovators are negotiating from a stronger position. Some agreements also include equity interest, warrants, or contractual rights that allow the original developer to participate in future value creation.
For global pharmaceutical companies, these arrangements offer access to promising drug candidates while distributing financial commitment across different stages of development.
Recent Developments Shaping Pharmaceutical Deal-Making
Record Overseas Licensing Activity in 2026
China’s biotechnology sector has experienced substantial growth in overseas licensing activity. Reuters reported that the total value of Chinese drugmakers’ overseas licensing agreements reached USD 139.4 billion by October 8, 2026, surpassing the full-year 2025 total of $138.8 billion.
The same report stated that upfront payments reached US$8 billion during the first three quarters of 2026, compared with US$7.2 billion for the whole of 2025.
The figures indicate growing international demand for Chinese drug discoveries and stronger commercial terms for developers. However, total deal values often include conditional future payments and should not be interpreted as completed revenue or guaranteed investment returns.
Hengrui Pharma Demonstrated a New Licensing Strategy
Jiangsu Hengrui Pharmaceuticals provides an example of how Chinese drugmakers are changing their approach to international partnerships.
In 2023, Hengrui licensed an asthma drug to the US biotechnology company Ailos under agreements reportedly worth around UD$1 billion upfront, with additional milestone payments of up to US$400 million.
Hengrui later adopted a different approach for three GLP-1 weight-loss drug candidates. It licensed the medicines to Hercules, a US-based company backed by Bain Capital, in a transaction payment. Hengrui also secured a 20% equity stake in the venture, which became Kailera Therapeutics and subsequently listed in New York in 2026.
The example illustrates how licensing agreements can provide more than immediate financial returns. Equity participation can give the original innovator exposure to the future value of a drug development business, although the ultimate return depends on clinical progress and commercial performance.
Global Partnerships Expand Beyond Traditional Licensing
Other Chinese biotechnology companies are experimenting with arrangements that offer broader economic participation. Reuters highlighted an example involving Keymed Bioscience. Genor Biopharma and Abogen Biosciences.
In October 2026, Abogen entered an agreement granting Novartis rights to autoimmune disease treatments, with options covering related assets contributing to a reported total transaction value of nearly UD$8 billion.
Such a structure can provide international partners with access to a broader group of potential therapies while giving Chinese developers additional opportunities to benefit from successful research.
For pharmaceutical companies, these agreements may help secure future pipeline options in competitive therapeutic areas. For Chinese innovators, they can improve negotiating power and reduce dependence on a single upfront licensing payment.
How Technology is Supporting China's Pharmaceutical Innovation
Technological progress is strengthening China's ability to discover, develop, and commercialize innovative medicines. Several developments are contributing to this transformation.
- Artificial intelligence in drug discovery: AI tools can analyze biological datasets, identify potential drug targets, predict molecular interactions, and help researchers prioritize promising compounds. These applications may improve research efficiency, although experimental validation and clinical trials remain essential.
- Advanced biologics development: Improvements in antibody engineering, protein design, and cell-based technologies are expanding opportunities to develop targeted treatments for cancer and immune-mediated diseases.
- Clinical research infrastructure: Established research centers, clinical trial networks, and contract research organizations can support drug development across multiple stages, helping companies coordinate studies and generate clinical evidence.
- Precision medicine: Genomic analysis, molecular diagnostics, and biomarker research can help developers investigate therapies for specific patient populations. These approaches may support more targeted treatment strategies where clinical evidence validates their use.
- Manufacturing capabilities: Specialized facilities and experienced biotechnology manufacturers can support the production of complex biological medicines. Reliable manufacturing and quality systems are particularly important when candidates progress toward larger clinical trials and commercialization.
Together, these capabilities can make Chinese biotechnology companies attractive development partners. However, technology alone does not guarantee successful medicines. Strong clinical evidence, manufacturing consistency, regulatory compliance, and commercial viability remain critical.
Key Challenges That Could Affect Cross-Border Pharmaceutical Deals
Despite growing international interest, several challenges could influence the future of pharmaceutical partnerships with China.
- Geopolitical and National Security Concerns: Relations between China and Western governments can affect biotechnology investments, data-sharing arrangements, and commercial partnerships. Concerns about sensitive biological data, research collaboration, and supply chain dependence may create additional scrutiny for cross-border transactions.If regulatory restrictions become more stringent, companies could face delays, higher compliance costs, or limitations on certain partnerships.
- Clinical and Regulatory Uncertainty: A promising drug candidate must demonstrate appropriate safety and effectiveness before receiving approval. Results from early-stage studies do not guarantee success in later trials, and regulators may require additional evidence for specific patient populations or indications. Multinational companies must independently evaluate clinical data, trial quality, manufacturing processes, and regulatory requirements before committing significant resources.
- Intellectual Property Protection: Intellectual property rights are central to licensing arrangements. Companies must establish clear ownership of drug candidates, patents, manufacturing processes, and related technologies. Uncertainty surrounding patent protection, contractual obligations, or ownership rights can complicate negotiations and affect the commercial value of a transaction.
- Commercial Competition and Pricing Pressure: Licensing a promising therapy does not guarantee commercial success. Drug candidates may face competition from established medicines, rival therapies, or treatments with stronger clinical evidence. Companies must also consider reimbursement policies, market access requirements, manufacturing expenses, and the pricing environment in each country. These factors influence whether a licensed medicine can generate sufficient returns.
- Dependence on International Partners: Chinese biotechnology companies may depend on multinational partners for late-stage clinical development, regulatory submissions, and international commercialization. Although partnerships provide valuable resources, developers can lose direct control over important decisions involving the future of their products.
Negotiating balanced agreements and retaining appropriate economic interests can help innovators capture more value while benefiting from global commercial expertise.
What the Future Holds for Global Pharmaceutical Innovation
The future of pharmaceutical innovation will likely involve greater collaboration between established multinational drugmakers and biotechnology companies operating in emerging research hubs, including China.
Global pharmaceutical companies may increasingly evaluate external drug candidates alongside their internal research programs. This approach could provide access to a broader range of therapeutic opportunities, diversify research pipelines, and help companies respond to changing medical needs.
Chinese biotechnology companies, meanwhile, may continue negotiating licensing agreements that include higher upfront payments, development milestones, royalties, and equity participation. These arrangements could help them build stronger financial positions while sharing the risks associated with drug development.
Oncology, autoimmune diseases, obesity, and other complex therapeutic areas are likely to remain important fields for collaboration because they offer opportunities for differentiated medicines and substantial unmet medical needs. AI-assisted discovery, antibody engineering, and precision medicine may create further opportunities for cross-border research.
India could also benefit from these developments through increased access to innovative medicines, research collaborations, clinical development opportunities, and potential technology transfer. However, access will depend on commercial licensing terms, regulatory approvals, pricing, and the availability of appropriate healthcare infrastructure.The long-term direction will also depend on how governments balance scientific collaboration with national security, data protection, and domestic industrial priorities.
Pharmaceutical companies will need strong compliance systems, transparent partnerships, and robust due diligence to manage these risks.
Ultimately, buying innovation from China is becoming a strategic way for multinational pharmaceutical companies to access promising science beyond their own laboratories. Its future success will depend on whether these partnerships translate promising discoveries into safe, effective, and commercially sustainable medicines.
Conclusion
Global pharmaceutical companies are increasingly buying innovation from China because the country's biotechnology ecosystem offers a growing range of drug candidates,
Scientific capabilities, and opportunities for strategic collaboration. Stronger research pipelines, advances in targeted therapies, and more sophisticated licensing agreements are helping Chinese developers establish a greater role in international pharmaceutical markets.
Recent dealmaking illustrates the scale of this shift. The US$139.4 billion in overseas licensing agreements reported by October 8, 2026, demonstrates the growing commercial importance of Chinese drug discoveries, although headline transaction values include conditional future payments.
Advances in AI, precision medicine, biologics development, and clinical reearch may further strengthen China's position. Nevertheless, geopolitical tensions, regulatory uncertainty, intellectual property concerns, and clinical development risks remain significant challenges.
As pharmaceutical companies increasingly combine internal research with external innovation, partnerships with Chinese biotechnology firms could become a more established part of global drug development. The central opportunity is not simply to acquire promising molecules but to combine scientific discoveries with the clinical expertise, regulatory capabilities, and commercial resources needed to bring effective medicines to patients worldwide.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.
Request Consultation